Solange Peters

Solange Peters, MD, PhD, is Head of Medical Oncology at the Lausanne University Hospital (CHUV) in Switzerland and a past President of the European Society for Medical Oncology (ESMO). She is one of Europe's foremost authorities on lung cancer immunotherapy and has made seminal contributions to the development and clinical validation of tumor mutational burden (TMB) as a predictive biomarker for checkpoint inhibitor benefit in NSCLC. Peters led key investigations within the IMpower program evaluating atezolizumab combinations in NSCLC, including the IMpower110 trial that demonstrated superior OS with atezolizumab monotherapy over chemotherapy in PD-L1 high (TC3 or IC3) first-line metastatic NSCLC. As ESMO President she championed guideline harmonization across lung cancer immunotherapy indications and facilitated international consensus on biomarker-driven treatment selection. Peters is deeply engaged in translational research on mechanisms of primary and acquired immunotherapy resistance, particularly the role of STK11/KEAP1 co-mutations in KRAS-mutant NSCLC in blunting PD-L1 pathway responses. She has served on the ESMO Clinical Practice Guidelines committee for lung cancer and chairs multiple international steering committees for ongoing phase III immunotherapy trials. Her dual commitment to clinical excellence and scientific rigor has made her one of the defining voices in European thoracic oncology.